@wilweten but I question the data and how humans respond to the maximum dose of 80 mcg. When I looked at results from clinical trials it gave data on many conditions that participants experienced, none of it actually an outcome of the medication apparently, but I don't recall seeing meaningful data on bone cancer. As for the rats, even at lower doses, a certain percentage of them developed bone cancer, just a lower percentage.

@wilweten Taken from online research: During drug testing, Tymlos (abaloparatide) caused a dose-dependent increase in a rare type of bone cancer called osteosarcoma in both male and female rats at exposures 4 to 28 times human levels. "It remains unknown if this risk applies to humans"